Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05647564 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET/CT Characterization of Treatment Resistance

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 3 months later across 2 updates Sep 1, 2026 → Dec 1, 2027
See other at-risk trials from University of Wisconsin, Madison

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 1, 2026 to Dec 1, 2027
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site contact updated
  2. Primary and study completion pushed from Sep 1, 2026 to Dec 1, 2026v17
  3. Primary and study completion dates: Mar 1, 2026 to Sep 1, 2026
    • Enrollment target: 20 to 25
    • Eligibility criteria expanded, about 2 words
    v16
  4. Site contact updatedv15
  5. Primary completion date: Mar 1, 2025 to Mar 1, 2026
    • Study completion date: Mar 1, 2027 to Mar 1, 2026
    v14
Show 12 earlier versionsHide 12 earlier versions
  1. Primary completion date: Mar 2025 to Mar 1, 2025
    • Study completion date: Mar 2027 to Mar 1, 2027
    v13
  2. Eligibility criteria expanded, about 1 word
    • Study description expanded, about 1 word
    v12
  3. Primary completion date: Sep 2024 to Mar 2025
    • Study completion date: Sep 2024 to Mar 2027
    v11
  4. Eligibility criteria shortened, about 7 wordsv10
  5. Re-verified, no change to tracked fieldsv9
  6. Eligibility criteria expanded, about 7 words
    • Study description expanded, about 8 words
    v8
  7. Phase: Not specified to Not applicablev7
  8. Start date changed from estimate of Mar 2023 to Mar 6, 2023v6
  9. Start date: Feb 2023 to Mar 2023v5
  10. Start date: Jan 2023 to Feb 2023v4
  11. Start date: Dec 2022 to Jan 2023v3
  12. Trial status: Not Yet Recruiting to Recruiting
    • Secondary endpoints: details revised at 1 of 3 entries
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.
Trial Details
NCT Number NCT05647564
Lead Sponsor University of Wisconsin, Madison
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov